JP2005041875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005041875A5 JP2005041875A5 JP2004214382A JP2004214382A JP2005041875A5 JP 2005041875 A5 JP2005041875 A5 JP 2005041875A5 JP 2004214382 A JP2004214382 A JP 2004214382A JP 2004214382 A JP2004214382 A JP 2004214382A JP 2005041875 A5 JP2005041875 A5 JP 2005041875A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- ace inhibitor
- ramipril
- atorvastatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 239000005541 ACE inhibitor Substances 0.000 claims 8
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 6
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 5
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 5
- 229960005370 atorvastatin Drugs 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- 229960003401 ramipril Drugs 0.000 claims 5
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 5
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 230000000747 cardiac effect Effects 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical group C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 2
- 108010061435 Enalapril Proteins 0.000 claims 2
- 108010007859 Lisinopril Proteins 0.000 claims 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims 2
- 229960004530 benazepril Drugs 0.000 claims 2
- 229960000830 captopril Drugs 0.000 claims 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960000873 enalapril Drugs 0.000 claims 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 2
- 229960002490 fosinopril Drugs 0.000 claims 2
- 229960002394 lisinopril Drugs 0.000 claims 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960002582 perindopril Drugs 0.000 claims 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims 2
- 229960001455 quinapril Drugs 0.000 claims 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 2
- 229960002051 trandolapril Drugs 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5727697P | 1997-08-29 | 1997-08-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000508363A Division JP2001514223A (ja) | 1997-08-29 | 1998-08-11 | アトルバスタチンと血圧降下薬とを含む組み合わせ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005041875A JP2005041875A (ja) | 2005-02-17 |
| JP2005041875A5 true JP2005041875A5 (enExample) | 2005-10-06 |
Family
ID=22009602
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000508363A Withdrawn JP2001514223A (ja) | 1997-08-29 | 1998-08-11 | アトルバスタチンと血圧降下薬とを含む組み合わせ療法 |
| JP2004214382A Withdrawn JP2005041875A (ja) | 1997-08-29 | 2004-07-22 | アトルバスタチンと血圧降下薬とを含む組み合わせ療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000508363A Withdrawn JP2001514223A (ja) | 1997-08-29 | 1998-08-11 | アトルバスタチンと血圧降下薬とを含む組み合わせ療法 |
Country Status (41)
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830887A (en) | 1992-05-19 | 1998-11-03 | Novogen Research Pty. Ltd. | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| KR20010041916A (ko) * | 1998-03-17 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제 |
| ATE242007T1 (de) | 1998-12-23 | 2003-06-15 | Searle Llc | Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| AU2007200367B2 (en) * | 1999-02-06 | 2010-04-08 | Astrazeneca Ab | Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| EE05670B1 (et) | 1999-08-30 | 2013-08-15 | Aventis Pharma Deutschland Gmbh | Ramipriil kardiovaskulaarsete haigusjuhtude rahoidmiseks |
| AUPQ266199A0 (en) | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| US7125897B1 (en) | 1999-09-24 | 2006-10-24 | Vasogen Ireland Limited | Combined therapies for atherosclerosis treatment |
| FR2803525B1 (fr) * | 2000-01-06 | 2002-05-03 | Sod Conseils Rech Applic | Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle |
| AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| SE0002354D0 (sv) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
| US20030207930A1 (en) | 2000-07-19 | 2003-11-06 | Erwin Marti | Valsartan salts |
| AU2001284413A1 (en) * | 2000-08-30 | 2002-03-13 | Sankyo Company Limited | Medicinal compositions for preventing or treating heart failure |
| US7018649B2 (en) * | 2000-10-23 | 2006-03-28 | Euro-Celtique, S.A. | Felodipine transdermal device and methods |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| AUPR255401A0 (en) * | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| BRPI0206641B8 (pt) | 2001-01-26 | 2021-05-25 | Merck Sharp & Dohme | uso de um inibidor da absorção de esteróis |
| SK288217B6 (sk) | 2001-01-26 | 2014-08-05 | Merck Sharp & Dohme Corp. | Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie |
| AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
| UA76475C2 (en) * | 2001-07-19 | 2006-08-15 | Pharmacia Corp | Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system |
| PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| US6852737B2 (en) | 2001-08-06 | 2005-02-08 | Recordati Ireland Limited | Crude and crystalline forms of lercanidipine hydrochloride |
| DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| AU2003207431A1 (en) | 2002-01-17 | 2003-09-02 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepines. |
| CA2490636A1 (en) * | 2002-06-20 | 2003-12-31 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
| CA2492060C (en) * | 2002-06-27 | 2011-11-01 | Sb Pharmco Puerto Rico Inc. | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
| AU2003251627A1 (en) * | 2002-06-27 | 2004-01-19 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydrobromide |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| GB0221579D0 (en) * | 2002-09-17 | 2002-10-23 | Pfizer Ltd | Combinations of atorvastatin and, adrenergic receptor antagonists |
| JP2006504800A (ja) * | 2002-10-16 | 2006-02-09 | レコーダチ アイルランド リミテッド | リシノプリル／レルカニジピンの組み合わせ治療 |
| AU2003291719A1 (en) | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| CN1756756A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| CA2517573C (en) | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| US20050169994A1 (en) * | 2003-11-25 | 2005-08-04 | Burke Matthew D. | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| WO2005051322A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts |
| JP2007512372A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール塩、対応する組成物、送達および／または治療方法 |
| KR20050092519A (ko) * | 2004-03-16 | 2005-09-22 | 화이자 인코포레이티드 | 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합 |
| EP1734958A1 (en) * | 2004-04-06 | 2006-12-27 | Merck & Co., Inc. | Methods for the treatment of hypertension |
| EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| US20060051418A1 (en) * | 2004-08-25 | 2006-03-09 | Essentialis, Inc. | Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
| ZA200706702B (en) * | 2005-02-17 | 2008-11-26 | Chiesi Farma Spa | Therapeutic combinations of manidi pine and a statin |
| CN101415425B (zh) | 2006-03-29 | 2014-11-26 | 兴和株式会社 | 甘油三酯降低剂和高胰岛素血症改善剂 |
| MX2009004681A (es) * | 2006-10-30 | 2009-08-19 | Hanall Pharmaceutical Co Ltd | Composicion compleja de liberacion controlada que comprende bloqueadores del receptor de angiotensina ii e inhibidores de hmg-coa-reductasa. |
| EP2281557A4 (en) | 2008-04-29 | 2011-08-31 | Hanall Biopharma Co Ltd | PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT |
| CZ2008740A3 (cs) * | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
| US9161933B2 (en) * | 2009-01-23 | 2015-10-20 | Hanmi Science Co., Ltd | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
| SI23149A (sl) * | 2009-09-21 | 2011-03-31 | Silverstone Pharma | Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
| RU2481124C1 (ru) * | 2011-10-27 | 2013-05-10 | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения |
| CN102671198A (zh) * | 2011-12-17 | 2012-09-19 | 东莞达信生物技术有限公司 | 一种降压降脂复方药及其制备方法 |
| KR20140028971A (ko) * | 2012-08-31 | 2014-03-10 | 한미약품 주식회사 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
| AU2014230304B2 (en) * | 2013-03-12 | 2018-07-05 | Lg Chem, Ltd. | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
| CN104173420A (zh) * | 2013-05-20 | 2014-12-03 | 广州诺氏刘生物科技有限公司 | 一种治疗急性肾衰竭的药物 |
| NZ731751A (en) | 2014-10-23 | 2023-07-28 | Arena Pharm Inc | Method of treating conditions related to the pgi2 receptor |
| CN108156807A (zh) * | 2015-06-30 | 2018-06-12 | 韩美药品株式会社 | 含有氨氯地平、氯沙坦和瑞舒伐他汀的药物复合制剂 |
| FR3040303B1 (fr) * | 2015-08-27 | 2019-04-05 | Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
| CN105232555A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法 |
| AU2017274438A1 (en) * | 2016-06-02 | 2018-12-13 | Ana Pharmaceuticals, Inc. | Methods and compositions for treatment of hypercalciuria and nephrolithiasis |
| MX2019008813A (es) | 2017-01-25 | 2020-02-12 | The George Inst For Global Health | Composiciones para el tratamiento de la hipertension. |
| CN110582271B (zh) | 2017-03-01 | 2022-06-14 | 阿瑞那制药公司 | 包含pgi2受体激动剂的组合物及其制备方法 |
| WO2019222764A1 (en) | 2018-05-16 | 2019-11-21 | Arena Pharmaceuticals, Inc. | Compositions comprising pgi2-receptor agonists and processes for the preparation thereof |
| EP3826633A4 (en) * | 2018-07-26 | 2022-04-27 | The George Institute For Global Health | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION |
| CN112826937B (zh) * | 2021-03-25 | 2022-03-22 | 山东大学齐鲁医院 | 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| NZ286920A (en) * | 1995-07-03 | 1997-06-24 | Sankyo Co | Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma |
| AU720853B2 (en) * | 1995-11-02 | 2000-06-15 | Warner-Lambert Company | Method and pharmaceutical composition for regulating lipid concentration |
-
1998
- 1998-08-07 GT GT199800126A patent/GT199800126A/es unknown
- 1998-08-11 AU AU84589/98A patent/AU740424B2/en not_active Ceased
- 1998-08-11 BR BR9811556-1A patent/BR9811556A/pt not_active Application Discontinuation
- 1998-08-11 HU HU0004318A patent/HUP0004318A3/hu unknown
- 1998-08-11 TR TR2000/00563T patent/TR200000563T2/xx unknown
- 1998-08-11 CN CN98808463A patent/CN1268053A/zh active Pending
- 1998-08-11 KR KR10-2003-7000672A patent/KR20030015394A/ko not_active Ceased
- 1998-08-11 ES ES98935250T patent/ES2234134T3/es not_active Expired - Lifetime
- 1998-08-11 PT PT98935250T patent/PT1009400E/pt unknown
- 1998-08-11 CN CNA031430929A patent/CN1473566A/zh active Pending
- 1998-08-11 IL IL13396298A patent/IL133962A0/xx not_active IP Right Cessation
- 1998-08-11 CA CA002296723A patent/CA2296723A1/en not_active Abandoned
- 1998-08-11 SK SK143-2000A patent/SK1432000A3/sk unknown
- 1998-08-11 YU YU2000A patent/YU2000A/sh unknown
- 1998-08-11 EA EA200000012A patent/EA200000012A1/ru unknown
- 1998-08-11 NZ NZ530630A patent/NZ530630A/en unknown
- 1998-08-11 WO PCT/IB1998/001230 patent/WO1999011260A1/en not_active Ceased
- 1998-08-11 NZ NZ502280A patent/NZ502280A/xx unknown
- 1998-08-11 KR KR10-2004-7019432A patent/KR20040106591A/ko not_active Ceased
- 1998-08-11 CN CNA031430937A patent/CN1473567A/zh active Pending
- 1998-08-11 PL PL98339091A patent/PL339091A1/xx unknown
- 1998-08-11 JP JP2000508363A patent/JP2001514223A/ja not_active Withdrawn
- 1998-08-11 AT AT98935250T patent/ATE285767T1/de not_active IP Right Cessation
- 1998-08-11 ID IDW20000196A patent/ID24118A/id unknown
- 1998-08-11 EP EP98935250A patent/EP1009400B1/en not_active Expired - Lifetime
- 1998-08-11 KR KR1020007001062A patent/KR20010022477A/ko not_active Ceased
- 1998-08-11 DE DE69828413T patent/DE69828413T2/de not_active Expired - Fee Related
- 1998-08-17 PA PA19988457901A patent/PA8457901A1/es unknown
- 1998-08-24 PE PE1998000769A patent/PE107099A1/es not_active Application Discontinuation
- 1998-08-26 MA MA25228A patent/MA26536A1/fr unknown
- 1998-08-26 TN TNTNSN98155A patent/TNSN98155A1/fr unknown
- 1998-08-26 DZ DZ980205A patent/DZ2595A1/xx active
- 1998-08-26 UY UY25155A patent/UY25155A1/es not_active Application Discontinuation
- 1998-08-27 AR ARP980104287A patent/AR016399A1/es unknown
- 1998-08-27 MY MYPI98003941A patent/MY121008A/en unknown
- 1998-08-27 CO CO98049139A patent/CO4970724A1/es unknown
- 1998-08-27 EG EG102598A patent/EG24678A/xx active
- 1998-08-27 AP APAP/P/1998/001332A patent/AP1191A/en active
- 1998-08-28 HR HR60/057,276A patent/HRP980474A2/hr not_active Application Discontinuation
- 1998-08-28 ZA ZA9807839A patent/ZA987839B/xx unknown
- 1998-09-30 SA SA98190603A patent/SA98190603B1/ar unknown
-
2000
- 2000-01-09 IL IL133962A patent/IL133962A/en unknown
- 2000-01-13 BG BG104075A patent/BG64724B1/bg unknown
- 2000-01-14 IS IS5341A patent/IS5341A/is unknown
- 2000-02-18 OA OA1200000040A patent/OA11291A/en unknown
- 2000-02-28 NO NO20000996A patent/NO323987B1/no unknown
-
2001
- 2001-10-23 US US10/045,329 patent/US20020099046A1/en not_active Abandoned
-
2003
- 2003-05-19 US US10/442,285 patent/US20030199492A1/en not_active Abandoned
-
2004
- 2004-07-22 JP JP2004214382A patent/JP2005041875A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005041875A5 (enExample) | ||
| JP2009256381A5 (enExample) | ||
| JP2005504064A5 (enExample) | ||
| CA2461958A1 (en) | Combination dosage form containing a cholesterol-lowering agent, a renin-angiotensin inhibitor, and aspirin | |
| JP2004513920A5 (enExample) | ||
| HUP0400475A2 (hu) | Egy AT1 receptor antagonista vagy egy ACE inhibitor vagy egy HMG-CO-A reduktáz inhibitor közül legalább két vegyület kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JP2010518028A5 (enExample) | ||
| RU96112139A (ru) | Фармацевтический препарат для перорального приема | |
| MX2010010479A (es) | Capsula para la prevencion de enfermedades cardiovasculares. | |
| RU2006102356A (ru) | Лечение и предотвращение сердечно-сосудистых заболеваний | |
| JP2010043111A (ja) | アムロジピンとベナゼプリル／ベナゼプリラートの治療上の組み合せ | |
| JP2003238444A5 (enExample) | ||
| FI4101454T3 (fi) | Koostumuksia käytettäviksi kohonneen verenpaineen hoitoon | |
| CN101612403A (zh) | 含钙拮抗剂、ace抑制剂和他汀类药的药物组合物 | |
| US20100239669A1 (en) | Combinations of statins and anti-obesity agent | |
| JP2005068010A5 (enExample) | ||
| CN104602678A (zh) | 包含厄贝沙坦和hmg-coa还原酶抑制剂的药物复合胶囊制剂 | |
| RU2011141908A (ru) | Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний | |
| RU2001122113A (ru) | Применение антагонистов рецептора ангиотензина II для лечения острого инфаркта миокарда | |
| RU2006135205A (ru) | Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда | |
| JP2005525391A5 (enExample) | ||
| CN108135882A (zh) | 包含HMG-CoA还原酶抑制剂和ACE抑制剂的药物组合物 | |
| HRP20170267T1 (hr) | Kombinacija (3s,3s') 4,4'-disulfandiilbis(3-aminobutan 1-sulfonske kiseline) i drugog antihipertenzivnog agensa | |
| RU2006128291A (ru) | Комбинация вориконазола и противогрибкового ингибитора cyp2c19 | |
| CN100430057C (zh) | 左旋氨氯地平和阿托伐他汀的药物组合物 |